At the ASCO meeting this week, the firm will present validation data on the test, which predicts response to immune checkpoint inhibitors in advanced melanoma.
At the ASCO meeting this week, the firm will present validation data on the test, which predicts response to immune checkpoint inhibitors in advanced melanoma.
OBI Pharma Announces First Patient Enrolled on SWOG Cancer Research Network's OBI-3424 Phase 1/2 Study Targeting AKR1C3 in T-ALL and T-LBL prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
OBI Pharma, Inc. to Present at the 39th J.P. Morgan Healthcare Conference
TAIPEI, Taiwan, Jan. 6, 2021 /PRNewswire/ OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), announced that Tillman Pearce, MD., Chief Medical Officer, will present a company and clinical development overview at the 39
th Annual J.P. Morgan Digital Healthcare Conference on Monday, January 11, 2021 at 11:00 a.m. EST/ 8:00 a.m. PST.
The presentation slides will be available online at www.obipharma.com on January 12, 2021.
About OBI Pharma
OBI Pharma, Inc., is a Taiwan biopharmaceutical company that was established in 2002. Its mission is to develop and license novel therapeutic agents for unmet medical needs against cancer targets such as Globo Series (including Globo H, SSEA-3 and SSEA-4), AKR1C3, and other promising targets.